autologous CD8+ cytotoxic T-lymphocyte clones targeting cancer-testis antigens

Autologous CD8+ cytotoxic T-lymphocyte clones targeting cancer-testis antigens is an investigational adoptive cell therapy (ACT) that utilizes a patient's own immune system to combat tumors. The process involves isolating CD8-positive T-cells from the patient, which are then screened and expanded ex vivo into specific clones that recognize peptides derived from cancer-testis antigens (CTAs)—such as MAGE-A1, MAGE-A3, or NY-ESO-1—presented on MHC class I molecules. Unlike CAR-T or TCR-T therapies that typically involve genetic engineering, this approach relies on the natural repertoire of T-cell receptors. Once re-infused, typically after a lymphodepleting conditioning regimen, these expanded clones selectively target and kill tumor cells expressing CTAs. Since CTAs are normally expressed only in the testes and placenta (immune-privileged sites), this therapy offers a high degree of tumor specificity with minimal off-target effects on healthy tissues.

Other names

autologous cancer-testis antigen-specific T-cell clonesCTA-specific CTL clonesautologous CD8+ T-cell clones targeting cancer-testis antigens